INFECTION PREVENTION References
1. Offi ce of Disease Prevention and Health Promotion. Adverse drug events.
https://health.gov/hcq/ade.asp
2. AAMI News. Helping smart pump technology deliver on its promise. November 2015.
https://www.aami.org/productspublica- tions/
articledetail.aspx?ItemNumber=2873
3. Optimizing safe implementation and use of smart infu- sion pumps: ISMP post summit draft safe practice statements.
https://www.ismp.org/sites/default/fi les/attachments/2019-03/
Final_DraftSmartPump_Guidelines.docx
4. Torio CM, Moore BJ. National inpatient hospital costs: the most expensive conditions by payer, 2013. Healthcare Cost and Utilization Project. Statistical Brief #204. May 2016.
5. Paoli CJ, Reynolds MA, Sinha M, et al. Epidemiology and costs of sepsis in the United States – an analysis based on timing of diagnosis and severity level. Crit Care Med. 2018 Dec;46(12) :1889-1897.
6. Prusch AE, Suess TM, Paoletti RD, et al. Integrating technology to improve medication administration. Am J Health Syst Pharm. 2011;68(9):835-842.
7. Kombau C, Lee KC, Hughes GD, et al. Central line complications. Int J Crit Illn Inj Sci. 2015 Jul-Sep; 5(3):170–178.
8. Pathak R, Patel A, Enuh H, et al. The incidence of central line–as- sociated bacteremia after the introduction of midline catheters in a ventilator unit population. Infect Dis Clin Pract (Baltim Md). 2015 May;23(3):131-134.
9. Thompson J, Garrett JH Jr. Transducer disinfection for evaluation and insertion of peripheral and central catheters for vascular access teams and clinicians. Journal of the Association for Vascular Access. 2018;23(3): 141-146.
10. Drafz M, Goeller K, et al. Efforts Toward standardization of UGPIV insertion through quantitative clinical product evaluation. Presented at the Association for Vascular Access Annual Scientifi c Meeting, Las Vegas, NV. October 2019. Poster.
Dale Medical Products' vascular- access stabilization device
catheters and the Hold-n-Place 852 for cen- tral venous catheter, peripherally inserted central catheter, and arterial sheath devices are built on a history of hypoallergenic skin- safe products.” The devices are made of a soft, fl exible, low-profi le material, with no hard plastic to irritate the skin or attract patients’ attention. “In most applications, no skin prep is required, and no alcohol is required for removal,” added Kyvik. The clinically familiar chevron secure- ment technique is adaptable to many dif- ferent single- and multi-lumen catheter confi gurations. Kyvik said that the chevron securement method prevents the rigid cath- eter hub and connectors from irritating the patient’s skin, reducing pistoning, twisting, and side-to-side movement of the catheter, keeping it secure from all directions, top, bottom, and sides.” Kyvik explained that the Dale Hold- n-Place securement device separates the functions of securement and transparent dressing to maximize catheter security and purchasing fl exibility. “Dale Hold-n-Place product numbers 848 and 854 feature a separate PrevahexCHX antimicrobial, trans- parent-fi lm dressing, for added protection against CRBSI. Dale has the fi rst and only securement kits to feature PrevahexCHX. Product numbers 849 and 853 feature a separate, regular, transparent dressing.”
Figuring it out
Whatever sort of infusion pump, catheter, or catheter-related device you are seeking to replace or upgrade, do your due diligence. Ask the vendor for the scientifi c evidence of effi cacy in the form of independent studies published in respected medical journals. Multiple studies confi rm claims of effi cacy, because if the product works, results from these studies can be duplicated in other independent tests. That is the evidence you are looking for, and the vendors will be delighted to make it available to you. HPN
Connect Smarter. Care Safer.
™
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
